BBI Brickell Biotech, Inc. Stock Quote

BBI [NASD]

Index	-	P/E	-	EPS (ttm)	-2.41	Insider Own	0.80%	Shs Outstand	53.52M	Perf Week	-19.05%
Market Cap	66.43M	Forward P/E	-	EPS next Y	-0.49	Insider Trans	13.33%	Shs Float	51.98M	Perf Month	-3.25%
Income	-24.40M	PEG	-	EPS next Q	-0.09	Inst Own	13.70%	Short Float	8.87%	Perf Quarter	93.50%
Sales	2.50M	P/S	26.57	EPS this Y	13.60%	Inst Trans	36.26%	Short Ratio	1.13	Perf Half Y	33.86%
Book/sh	0.67	P/B	1.78	EPS next Y	31.00%	ROA	-114.80%	Target Price	-	Perf Year	-57.50%
Cash/sh	0.36	P/C	3.29	EPS next 5Y	-	ROE	-187.40%	52W Range	0.47 - 3.44	Perf YTD	52.47%
Dividend	-	P/FCF	-	EPS past 5Y	19.10%	ROI	-291.40%	52W High	-65.41%	Beta	0.34
Dividend %	-	Quick Ratio	3.50	Sales past 5Y	-12.30%	Gross Margin	-	52W Low	155.36%	ATR	0.16
Employees	15	Current Ratio	3.50	Sales Q/Q	-91.70%	Oper. Margin	-	RSI (14)	44.65	Volatility	12.17% 11.37%
Optionable	No	Debt/Eq	0.03	EPS Q/Q	90.70%	Profit Margin	-	Rel Volume	0.56	Prev Close	1.32
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	4.06M	Price	1.19
Recom	1.50	SMA20	-11.06%	SMA50	7.59%	SMA200	26.00%	Volume	2,271,691	Change	-9.85%

Aug-28-20

Initiated

Lake Street

Buy

Aug-25-20

Initiated

Oppenheimer

Outperform

Feb-25-21 04:05PM	Brickell Biotech to Participate in March Virtual Investor Conferences GlobeNewswire -9.85%
Feb-23-21 04:01PM	Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021 GlobeNewswire -12.95%
Jan-19-21 07:00AM	Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology GlobeNewswire
Jan-06-21 12:50AM	Reflecting on Brickell Biotech's (NASDAQ:BBI) Share Price Returns Over The Last Year Simply Wall St. -11.48%
Dec-07-20 07:30AM	Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study GlobeNewswire
Nov-18-20 07:00AM	Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical GlobeNewswire +14.18%
Nov-16-20 08:00AM	Brickell Biotech to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-12-20 04:01PM	Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Brickell Biotech Inc to Host Earnings Call ACCESSWIRE
Oct-29-20 08:00AM	Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020 GlobeNewswire
Oct-22-20 08:00PM	Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering GlobeNewswire -13.19%
Sep-29-20 10:30AM	Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100% TipRanks +5.71%
Sep-25-20 07:00AM	Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical GlobeNewswire
Sep-10-20 04:05PM	Brickell Biotech to Participate in September Virtual Investor Conferences GlobeNewswire
Sep-08-20 07:30AM	AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S. GlobeNewswire
Aug-31-20 04:05PM	Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office GlobeNewswire
Aug-12-20 04:01PM	Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-20 04:05PM	Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020 GlobeNewswire
Jun-17-20 10:00PM	Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering GlobeNewswire -24.12%
Jun-15-20 06:30AM	Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical GlobeNewswire +50.00%
May-31-20 08:04AM	Brickell Biotech (NASDAQ:BBI) Is Arguably In A Tricky Situation Simply Wall St.
May-13-20 04:01PM	Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +13.25%
May-04-20 04:05PM	Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020 GlobeNewswire
Mar-18-20 04:01PM	Brickell Biotech Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire -10.94%
02:30PM	Brickell Biotech Inc to Host Earnings Call ACCESSWIRE
Mar-09-20 04:05PM	Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020 GlobeNewswire -7.23%
Mar-04-20 06:30AM	Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide GlobeNewswire
Feb-20-20 11:43AM	Heres Why E*Trade (ETFC), Adesto (IOTS) and Brickell Biotech (BBI) Shares Skyrocketed Today TipRanks +68.13%
06:30AM	Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology GlobeNewswire
Feb-18-20 06:30AM	Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements GlobeNewswire +42.24%
Jan-10-20 04:05PM	Brickell Bios Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis GlobeNewswire -5.00%
Nov-13-19 04:05PM	Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Oct-30-19 04:42PM	Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest GlobeNewswire
Sep-03-19 06:45AM	Brickell Biotech Completes Merger with Vical GlobeNewswire

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McAvoy David R.	General Counsel and CCO	Sep 18	Buy	0.84	6,000	5,039	6,000	Sep 21 04:19 PM
McAvoy David R.	General Counsel and CCO	Sep 18	Buy	0.83	16,526	13,713	75,883	Sep 21 04:19 PM
VERU DENNISON T	Director	Sep 16	Buy	0.80	14,645	11,758	50,810	Sep 17 05:07 PM
VERU DENNISON T	Director	Sep 15	Buy	0.81	15,355	12,416	36,165	Sep 17 05:07 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience